Cargando…
Prioritization of antiretroviral therapy in patients with high CD4 counts, and retention in care: lessons from the START and Temprano trials
Initiation of antiretroviral therapy is not a once in a lifetime opportunity. In some resource constrained settings financial limitations make it necessary to prioritize treatment initiation for some groups of patients. In developed countries, there are patients who are reluctant to initiate treatme...
Autor principal: | Schechter, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810323/ https://www.ncbi.nlm.nih.gov/pubmed/29436779 http://dx.doi.org/10.1002/jia2.25077 |
Ejemplares similares
-
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy
por: Jose, Sophie, et al.
Publicado: (2014) -
The Continuing Value of CD4 Cell Count Monitoring for Differential HIV Care and Surveillance
por: Rice, Brian, et al.
Publicado: (2019) -
Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs
Publicado: (2018) -
Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial
por: Baker, Jason V., et al.
Publicado: (2016) -
Childhood Tuberculosis: An Under Prioritized Disease in Nepal
por: Gautam, Rabin, et al.
Publicado: (2021)